{"id":77486,"date":"2026-02-16T00:03:48","date_gmt":"2026-02-16T00:03:48","guid":{"rendered":"https:\/\/english.saigonbiz.com\/vn\/sapu-bioscience-expands-international-ip-coverage-for-ot-101-strengthening-cns-and-neurology-commercialization-pathway\/"},"modified":"2026-02-16T00:03:48","modified_gmt":"2026-02-16T00:03:48","slug":"sapu-bioscience-expands-international-ip-coverage-for-ot-101-strengthening-cns-and-neurology-commercialization-pathway","status":"publish","type":"post","link":"https:\/\/english.saigonbiz.com\/vn\/sapu-bioscience-expands-international-ip-coverage-for-ot-101-strengthening-cns-and-neurology-commercialization-pathway\/","title":{"rendered":"Sapu Bioscience Expands International IP Coverage for OT-101, Strengthening CNS and Neurology Commercialization Pathway"},"content":{"rendered":"<div>\n<p align=\"justify\"><strong>SAN DIEGO, CA, Feb.  16, 2026  (GLOBE NEWSWIRE) &#8212; Sapu Bioscience<\/strong> today announced advancements in its global IP portfolio supporting <strong>OT-101<\/strong>, its proprietary TGF-\u03b2 antisense therapeutic platform, strengthening protection across neurology, oncology, and CNS drug delivery.<\/p>\n<p align=\"justify\"><strong>Background on OT-101<\/strong><\/p>\n<p align=\"justify\">OT-101 (TGF-\u03b2 antisense inhibitor) is a clinical-stage therapeutic with prior oncology trials including glioblastoma and pancreatic cancers. The Company is advancing OT-101 as a CNS-capable therapeutic platform, supported by targeted delivery technologies and expanded IP coverage.<\/p>\n<p align=\"justify\"><strong>Parkinson\u2019s Disease<\/strong><\/p>\n<p align=\"justify\">In Australia, the Company has received allowed patent claims covering OT-101 (SEQ ID NO:9) for treating Parkinson\u2019s Disease, including excessive daytime sleepiness and insomnia. The claims cover methods of treatment, manufacture-of-medicament claims, and CNS delivery routes including intrathecal and intracranial infusion.<\/p>\n<p align=\"justify\"><strong>Intracranial Delivery Device<\/strong><\/p>\n<p align=\"justify\">In China and Germany, utility model patents for \u201cDevice for Delivering Fluid Pharmaceutical Compositions by Intracranial Continuous Infusion\u201d have been granted (CN 222693486 U, effective April 1, 2025; DE 21 2023 000 368.6, term through 2033), providing device-level protection for continuous intracranial infusion technologies.<\/p>\n<p align=\"justify\"><strong>Strategic Impact<\/strong><\/p>\n<p align=\"justify\">These IP developments establish an integrated OT-101 CNS commercialization platform combining therapeutic use claims with granted delivery-device protection, enhancing OT-101\u2019s strategic value for development, partnering, and commercialization.<\/p>\n<p align=\"justify\"><strong>Management Commentary<\/strong><\/p>\n<p align=\"justify\">\u201cThese patent grants represent a pivotal inflection point for OT-101\u2019s development,\u201d said <strong>Dr. Vuong Trieu, CEO<\/strong>. \u201cBy securing method-of-treatment claims for Parkinson\u2019s Disease alongside granted device patents for intracranial delivery, we have built an integrated IP fortress around our CNS strategy, positioning OT-101 as a fully protected platform\u2014from molecule to delivery device\u2014ready for strategic partnering and clinical advancement.\u201d<\/p>\n<p align=\"justify\">The Company will present at BIO-Europe Spring on March 23\u201325, 2026, featuring data on OT-101 and its Deciparticle<sup>&#x2122;<\/sup> leading candidate: Sapu003 \u2013 intravenous everolimus.<\/p>\n<p align=\"justify\"><strong>About OT-101<\/strong><\/p>\n<p align=\"justify\">OT-101 is a clinical-stage TGF-\u03b2 antisense inhibitor with clinical history in glioblastoma and pancreatic cancer, now advanced as a CNS-capable therapeutic platform with expanded IP protection.<\/p>\n<p align=\"justify\"><strong>About the Deciparticle<\/strong><sup><strong>&#x2122;<\/strong><\/sup><strong> Platform<\/strong><\/p>\n<p align=\"justify\">The Deciparticle<sup>&#x2122;<\/sup> platform is a proprietary nanotechnology encapsulating hydrophobic molecules as sub-20 nm nanoparticles for intravenous administration, improving systemic exposure and enabling precision delivery at clinical scale.<\/p>\n<p align=\"justify\"><strong>About Sapu Bioscience<\/strong><\/p>\n<p align=\"justify\">Sapu Bioscience is a clinical-stage biotechnology company advancing proprietary platforms in oncology and neurology, including OT-101 and the Deciparticle<sup>&#x2122;<\/sup> nanomedicine platform, with an ISO-5 cGMP manufacturing facility.<\/p>\n<p align=\"justify\">For more information, visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=hVyslA_cGNNNhhYkR_q0NfNrJ7MaMbemEPm5L2MyIgOgvqeXrtRdzAOyF8UdrKW3YvESto8KMeP7ZDOtbY2xHf2VBQ9BA6HEm0cDU7xv-2g=\" rel=\"nofollow\" target=\"_blank\" title=\"\"><u>www.sapubio.com<\/u><\/a>.<\/p>\n<p align=\"justify\"><strong>Contact Information:<\/strong><\/p>\n<p align=\"justify\">For Sapu Bioscience:<br \/>Investor Relations<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=XO0eGyNg8e0kjZRDs7mgawY_WJ4yyTxR-_tQa9qJaet0pSsbt7WpK7qDr99w4kmN2I-gKYIOTSyrTiya-yaJJA==\" rel=\"nofollow\" target=\"_blank\" title=\"\"><u>ir@sapubio.com<\/u><\/a><\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/NmVhN2NjOTktNWE4Ni00ZDQ5LTk3MDAtZmU0M2I1NTQ3Y2FlLTUwMDE0OTU1NS0yMDI2LTAyLTE1LWVu\/tiny\/Sapu-Bioscience-LLC.png\" referrerpolicy=\"no-referrer-when-downgrade\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>SAN DIEGO, CA, Feb. 16, 2026 (GLOBE NEWSWIRE) &#8212; Sapu Bioscience today announced advancements in its global IP portfolio supporting OT-101, its proprietary TGF-\u03b2 antisense therapeutic platform, strengthening protection across neurology, oncology, and CNS drug delivery. Background on OT-101 OT-101 (TGF-\u03b2 antisense inhibitor) is a clinical-stage therapeutic with prior oncology trials including glioblastoma and pancreatic [&#8230;]\n","protected":false},"author":1,"featured_media":77487,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-77486","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-pr-newswire"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v21.6 (Yoast SEO v21.6) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Sapu Bioscience Expands International IP Coverage for OT-101, Strengthening CNS and Neurology Commercialization Pathway - Biz and Live in Saigon<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/english.saigonbiz.com\/vn\/sapu-bioscience-expands-international-ip-coverage-for-ot-101-strengthening-cns-and-neurology-commercialization-pathway\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Sapu Bioscience Expands International IP Coverage for OT-101, Strengthening CNS and Neurology Commercialization Pathway\" \/>\n<meta property=\"og:description\" content=\"SAN DIEGO, CA, Feb. 16, 2026 (GLOBE NEWSWIRE) &#8212; Sapu Bioscience today announced advancements in its global IP portfolio supporting OT-101, its p\" \/>\n<meta property=\"og:url\" content=\"https:\/\/english.saigonbiz.com\/vn\/sapu-bioscience-expands-international-ip-coverage-for-ot-101-strengthening-cns-and-neurology-commercialization-pathway\/\" \/>\n<meta property=\"og:site_name\" content=\"Biz and Live in Saigon\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/SaigonbizGroup\" \/>\n<meta property=\"article:published_time\" content=\"2026-02-16T00:03:48+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/02\/Sapu-Bioscience-LLC.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1\" \/>\n\t<meta property=\"og:image:height\" content=\"1\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"admin\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"admin\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/sapu-bioscience-expands-international-ip-coverage-for-ot-101-strengthening-cns-and-neurology-commercialization-pathway\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/sapu-bioscience-expands-international-ip-coverage-for-ot-101-strengthening-cns-and-neurology-commercialization-pathway\/\"},\"author\":{\"name\":\"admin\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/267b348e6cf32a66aab33637c2d399a6\"},\"headline\":\"Sapu Bioscience Expands International IP Coverage for OT-101, Strengthening CNS and Neurology Commercialization Pathway\",\"datePublished\":\"2026-02-16T00:03:48+00:00\",\"dateModified\":\"2026-02-16T00:03:48+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/sapu-bioscience-expands-international-ip-coverage-for-ot-101-strengthening-cns-and-neurology-commercialization-pathway\/\"},\"wordCount\":396,\"publisher\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#organization\"},\"articleSection\":[\"Pr Newswire\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/sapu-bioscience-expands-international-ip-coverage-for-ot-101-strengthening-cns-and-neurology-commercialization-pathway\/\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/sapu-bioscience-expands-international-ip-coverage-for-ot-101-strengthening-cns-and-neurology-commercialization-pathway\/\",\"name\":\"Sapu Bioscience Expands International IP Coverage for OT-101, Strengthening CNS and Neurology Commercialization Pathway - Biz and Live in Saigon\",\"isPartOf\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#website\"},\"datePublished\":\"2026-02-16T00:03:48+00:00\",\"dateModified\":\"2026-02-16T00:03:48+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/sapu-bioscience-expands-international-ip-coverage-for-ot-101-strengthening-cns-and-neurology-commercialization-pathway\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/english.saigonbiz.com\/vn\/sapu-bioscience-expands-international-ip-coverage-for-ot-101-strengthening-cns-and-neurology-commercialization-pathway\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/sapu-bioscience-expands-international-ip-coverage-for-ot-101-strengthening-cns-and-neurology-commercialization-pathway\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/english.saigonbiz.com\/vn\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Sapu Bioscience Expands International IP Coverage for OT-101, Strengthening CNS and Neurology Commercialization Pathway\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#website\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/\",\"name\":\"Biz and Live in Saigon\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/english.saigonbiz.com\/vn\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#organization\",\"name\":\"SaigonBiz Media\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/cropped-c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview.png\",\"contentUrl\":\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/cropped-c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview.png\",\"width\":512,\"height\":512,\"caption\":\"SaigonBiz Media\"},\"image\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/SaigonbizGroup\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/267b348e6cf32a66aab33637c2d399a6\",\"name\":\"admin\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview-2_uwp_avatar_thumb.png\",\"contentUrl\":\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview-2_uwp_avatar_thumb.png\",\"caption\":\"admin\"},\"sameAs\":[\"https:\/\/english.saigonbiz.com\/vn\"],\"url\":\"https:\/\/english.saigonbiz.com\/vn\/profile\/admin\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Sapu Bioscience Expands International IP Coverage for OT-101, Strengthening CNS and Neurology Commercialization Pathway - Biz and Live in Saigon","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/english.saigonbiz.com\/vn\/sapu-bioscience-expands-international-ip-coverage-for-ot-101-strengthening-cns-and-neurology-commercialization-pathway\/","og_locale":"en_US","og_type":"article","og_title":"Sapu Bioscience Expands International IP Coverage for OT-101, Strengthening CNS and Neurology Commercialization Pathway","og_description":"SAN DIEGO, CA, Feb. 16, 2026 (GLOBE NEWSWIRE) &#8212; Sapu Bioscience today announced advancements in its global IP portfolio supporting OT-101, its p","og_url":"https:\/\/english.saigonbiz.com\/vn\/sapu-bioscience-expands-international-ip-coverage-for-ot-101-strengthening-cns-and-neurology-commercialization-pathway\/","og_site_name":"Biz and Live in Saigon","article_publisher":"https:\/\/www.facebook.com\/SaigonbizGroup","article_published_time":"2026-02-16T00:03:48+00:00","og_image":[{"width":1,"height":1,"url":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/02\/Sapu-Bioscience-LLC.png","type":"image\/png"}],"author":"admin","twitter_card":"summary_large_image","twitter_misc":{"Written by":"admin","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/english.saigonbiz.com\/vn\/sapu-bioscience-expands-international-ip-coverage-for-ot-101-strengthening-cns-and-neurology-commercialization-pathway\/#article","isPartOf":{"@id":"https:\/\/english.saigonbiz.com\/vn\/sapu-bioscience-expands-international-ip-coverage-for-ot-101-strengthening-cns-and-neurology-commercialization-pathway\/"},"author":{"name":"admin","@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/267b348e6cf32a66aab33637c2d399a6"},"headline":"Sapu Bioscience Expands International IP Coverage for OT-101, Strengthening CNS and Neurology Commercialization Pathway","datePublished":"2026-02-16T00:03:48+00:00","dateModified":"2026-02-16T00:03:48+00:00","mainEntityOfPage":{"@id":"https:\/\/english.saigonbiz.com\/vn\/sapu-bioscience-expands-international-ip-coverage-for-ot-101-strengthening-cns-and-neurology-commercialization-pathway\/"},"wordCount":396,"publisher":{"@id":"https:\/\/english.saigonbiz.com\/vn\/#organization"},"articleSection":["Pr Newswire"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/english.saigonbiz.com\/vn\/sapu-bioscience-expands-international-ip-coverage-for-ot-101-strengthening-cns-and-neurology-commercialization-pathway\/","url":"https:\/\/english.saigonbiz.com\/vn\/sapu-bioscience-expands-international-ip-coverage-for-ot-101-strengthening-cns-and-neurology-commercialization-pathway\/","name":"Sapu Bioscience Expands International IP Coverage for OT-101, Strengthening CNS and Neurology Commercialization Pathway - Biz and Live in Saigon","isPartOf":{"@id":"https:\/\/english.saigonbiz.com\/vn\/#website"},"datePublished":"2026-02-16T00:03:48+00:00","dateModified":"2026-02-16T00:03:48+00:00","breadcrumb":{"@id":"https:\/\/english.saigonbiz.com\/vn\/sapu-bioscience-expands-international-ip-coverage-for-ot-101-strengthening-cns-and-neurology-commercialization-pathway\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/english.saigonbiz.com\/vn\/sapu-bioscience-expands-international-ip-coverage-for-ot-101-strengthening-cns-and-neurology-commercialization-pathway\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/english.saigonbiz.com\/vn\/sapu-bioscience-expands-international-ip-coverage-for-ot-101-strengthening-cns-and-neurology-commercialization-pathway\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/english.saigonbiz.com\/vn\/"},{"@type":"ListItem","position":2,"name":"Sapu Bioscience Expands International IP Coverage for OT-101, Strengthening CNS and Neurology Commercialization Pathway"}]},{"@type":"WebSite","@id":"https:\/\/english.saigonbiz.com\/vn\/#website","url":"https:\/\/english.saigonbiz.com\/vn\/","name":"Biz and Live in Saigon","description":"","publisher":{"@id":"https:\/\/english.saigonbiz.com\/vn\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/english.saigonbiz.com\/vn\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/english.saigonbiz.com\/vn\/#organization","name":"SaigonBiz Media","url":"https:\/\/english.saigonbiz.com\/vn\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/logo\/image\/","url":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/cropped-c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview.png","contentUrl":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/cropped-c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview.png","width":512,"height":512,"caption":"SaigonBiz Media"},"image":{"@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/SaigonbizGroup"]},{"@type":"Person","@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/267b348e6cf32a66aab33637c2d399a6","name":"admin","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/image\/","url":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview-2_uwp_avatar_thumb.png","contentUrl":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview-2_uwp_avatar_thumb.png","caption":"admin"},"sameAs":["https:\/\/english.saigonbiz.com\/vn"],"url":"https:\/\/english.saigonbiz.com\/vn\/profile\/admin\/"}]}},"_links":{"self":[{"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/posts\/77486","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/comments?post=77486"}],"version-history":[{"count":0,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/posts\/77486\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/media\/77487"}],"wp:attachment":[{"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/media?parent=77486"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/categories?post=77486"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/tags?post=77486"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}